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In this issue of Cancer Cell, Meuwissen, Berns, and colleagues
describe an invaluable new tool in the study of human small cell
lung cancer (SCLC), one that is likely to improve our under-
standing of disease development and provide a badly needed
means to test potential therapies and prevention strategies
(Figure 1) (Meuwissen et al., 2003). Using cutting-edge meth-
ods in genetic engineering in the mouse, they have produced an
animal model of SCLC with remarkable similarity to the human
disease.This model utilizes mice carrying Cre-LoxP-based con-
ditional (or “floxed”) alleles of the retinoblastoma (Rb) and p53
tumor suppressor genes. Deletion of these genes in cells of the
lung was achieved through intrabrochial injection of a recombi-
nant adenovirus expressing the Cre recombinase (Ad-Cre).This
method reproducibly resulted in the development of lung tumors
with the histologic, immunohistochemical, and metastatic
behavior of human SCLC. Tumors invariably showed deletion of
the two alleles of Rb and p53, demonstrating the importance of
loss of these two important tumor suppressor genes in SCLC
development. This model is quite distinct from the previous
mouse models of lung cancer, including those induced by
chemical carcinogens or through activation of the K-ras or other
oncogenes (Fisher et al., 2001; Jackson et al., 2001; Johnson et
al., 2001; Malkinson, 2001; Tuveson and Jacks, 1999). These
prior models predominantly developed lung adenomas and, in
some cases, adenocarcinomas, but never tumors with neuroen-
docrine features as seen in SCLC. Also, the tumors in these
earlier models rarely metastasize, a common feature of their
human counterparts.
To understand the value of the Meuwissen et al. model, a
brief summary of human SCLC and its treatment is needed
(Minna et al., 2002; Pass et al., 2000; Simon and Wagner,
2003). SCLC represents ?20% of new lung cancer cases in the
U.S.A., giving ?42,000 new SCLC cases each year. SCLC usu-
ally presents with pulmonary symptoms and bulky primary
tumors in the chest along with mediastinal lymph node metas-
tases. SCLC can metastasize around the body, and common
metastatic sites are brain, liver, bone, bone marrow, pleural
space, adrenal glands, and lymph nodes. Current standard of
care involves establishing a histologic diagnosis of SCLC with
biopsies usually obtained from bronchoscopy, careful staging to
define anatomically the location of the disease (with computed
tomography scans), and physiologic evaluation of the patient to
evaluate their ability to tolerate treatment. Clinically, the disease
is divided into “limited” and “extensive” stage disease with limit-
ed stage disease confined to the lung and regional thoracic
lymph nodes that operationally can be encompassed in a toler-
able radiation therapy port. Extensive stage disease represents
extra thoracic metastatic disease. Staging is followed by treat-
ment with either combination chemotherapy alone for extensive
stage disease (common regimens include cisplatin and etopo-
side or irinotecan and cisplatin) or combination chemotherapy
plus thoracic radiotherapy for limited stage disease, and radio-
therapy as needed for symptomatic metastatic sites (e.g., brain
metastases or painful boney metastases) that do not respond to
chemotherapy (Pass et al., 2000; Sandler, 2003; Turrisi, 2003).
Surgery is reserved for a small minority of patients with very
small primary tumors because of the nearly universal presence
of microscopic, extra-thoracic metastatic disease. Overall,
?20% of limited stage and ?5% of extensive stage patients
have very prolonged survival (>5 years) and may be potentially
cured while the large majority of patients have median survivals
of 12–36 months and eventually die of their disease. Over 90%
of patients’ tumors respond dramatically to initial chemotherapy
or chemo-radiotherapy with tumor shrinkage and relief of symp-
toms; overall, ?25% obtain a clinical “complete response”
where careful re-staging fails to disclose residual tumor. This is
the group that has the longest survival.
At tumor relapse, a variety of chemotherapy regimens can
be given including experimental therapies, and while tumor
responses of 10%–20% are seen, they only last for a few
months and the patient subsequently undergoes progressive
tumor growth and dies. It has taken the clinical research com-
munity 30 years to get to this point through a series of laborious,
complex, and expensive clinical trials, and at a recent interna-
tional lung cancer meeting, only minimal advances were report-
ed.While SCLC is considerably more responsive to chemo- and
radiotherapy than the other types of lung cancer collectively
called “non-small cell lung cancer” (NSCLC), clearly new thera-
peutic approaches are urgently needed. It is our opinion that the
Meuwissen et al. mouse model provides the first major tool for
preclinical trials to help develop new therapeutic approaches to
this type of lung cancer. In addition, it provides an important
system for investigating fundamental aspects of tumor initiation
and progression.
There has been extensive molecular analysis of human
SCLC and the earliest major findings included the observation
that >95% of human SCLCs have sustained mutations p53 and
Rb (Sattler and Salgia, 2003; Sekido et al., 2003; Wistuba et al.,
2001; Zochbauer-Muller et al., 2002).This occurs by mutation in
one allele (usually a missense mutation for p53 and truncating
M I N I R E V I E W
A big step in the study of small cell lung cancer
John D. Minna,1,* Jonathan M. Kurie,2 and Tyler Jacks3
1Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390
2Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
77030
3Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142
*Correspondence: john.minna@utsouthwestern.edu
A rationally designed, conditional p53 and Rb allele-based and lung-targeted mouse model of human small cell lung cancer
(SCLC) provides the cancer research community with a valid and important new tool to use in translational research against
this deadly disease.
164 CANCER CELL : SEPTEMBER 2003
mutations for Rb) and loss of the remaining wild-type allele.
Therefore, deletion of these two genes in the relevant cells of
the lung in the mouse was a logical approach to creating a
model of the disease. Indeed, animals with compound germline
mutations in Rb and p53 (Rb+/−; p53−/−) do develop lesions that
resemble precursors to SCLC, but these mice quickly succumb
to a host of other tumors, and the lung lesions do not progress
to true cancers (Williams et al., 1994). Two technological inno-
vations were needed for the development of the Meuwissen et
al. mouse model. First was the creation of floxed alleles of Rb
and p53, which permitted the directed mutation of these genes
in cells and tissues of interest while avoiding the development of
the spontaneous tumors seen in mice with germline deletions in
these genes (Vooijs et al., 1998; Jonkers et al., 2001). The sec-
ond important technical advance was the use of adenovirus
infection to deliver the Cre recombinase to the lung epithelium
in a fashion that did not assume what cell type(s) were needed
to undergo Rb/p53 deletion in order to initiate tumor develop-
ment.This approach has been perfected recently in similar stud-
ies involving activation of conditional oncogenic alleles of K-ras
(Jackson et al., 2001; Meuwissen et al., 2001). Interestingly,
despite the common methodology used, K-ras activation leads
to NSCLC-like tumors, whereas Rb/p53 deletion produces
tumors with SCLC features. These results indicate either that
different cell types in the lung are responsive to these different
oncogenic mutations or that the same cell type (likely a precur-
sor cell in the lung) progresses down distinct tumorigenic path-
ways when initiated by K-ras activation versus Rb/p53 deletion.
The coexistence of SCLC and NSCLC in the Meuwissen model
will facilitate the study of these two possibilities. Importantly, in
both types of models, it is likely that additional events (genetic
or epigenetic) are required for disease progression because not
all early lesions progress to advanced tumors.
Thus, one of the first uses of these new mouse models is to
provide tumor material to search in a genome-wide fashion for
all of the genetic and epigenetic changes leading to lung can-
cer. For example, other common oncogenic changes in SCLC
include frequent deregulated expression of one of the myc fam-
ily of oncogenes (c-myc, N-myc, or L-myc) and nearly universal
epigenetic inactivation (by DNA promoter methylation) of the
3p21.3 TSG RASSF1A (Sattler and Salgia, 2003; Sekido et al.,
2003; Wistuba et al., 2001; Zochbauer-Muller et al., 2002). It will
be important to know if these other common changes are found
in the Meuwissen et al. model. In addition, it should now be pos-
sible to determine whether other mutations (e.g., conditional
inactivation of the RASSF1A locus) combined with either condi-
tional inactivation of p53 or Rb leads to SCLC development.
Likewise, the targeting of TSG candidates in the human 3p21.3
chromosomal region (syntenic with portions of mouse chromo-
some 9) is important because careful laser capture microdis-
section studies have shown that allele loss at this very defined
locus is perhaps the earliest detected genetic change in smok-
ing-damaged bronchial epithelium; allele loss at 13q14 (Rb
locus) or 17p13 (p53 locus) comes later (Sekido et al., 2003;
Wistuba et al., 2000, 2001; Zochbauer-Muller et al., 2002).
Thus, the order of the events may also be important in tumor
progression and in model development. It will be interesting to
use the current model to learn the fate of other cells in the lung
that suffered Rb and p53 mutations but did not progress to full-
fledged lung cancer. The addition of conditional alleles of
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Figure 1. Illustration of the design of the Meuwissen SCLC model and its sites of metastasis
A: Mice that carry Rb and p53 genes with flanking LoxP sites underwent intratracheal delivery of a recombinant adenoviral vector expressing the Cre
recombinase (Ad-Cre), which cleaves DNA specifically at LoxP sites. In those mice that experienced homozygous loss of both Rb and p53, SCLC 
developed.
B: SCLC metastases were detected in the mouse model in sites commonly involved in SCLC patients. While the frequencies of metastatic involvement in the
mouse model were not described (Meuwissen et al., 2003), the percentages of newly diagnosed SCLC patients with extra-thoracic metastases are, by site,
19%38% (bone), 17%34% (liver), 5%-31% (adrenal glands), 17%23% (bone marrow), 0%14% (brain), 7%25% (lymph nodes), and 3%11% (soft tissues) (Ihde
et al., 1997).
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reporter genes, such as LacZ or GFP, will be very useful in this
regard. Finally, this model is very well suited to studying the ear-
lier events in tumor initiation and progression, including the
identification of the cell of origin of SCLC and its relationship to
precursor or stem cells in the lung.
Any preclinical model needs to be carefully characterized
before being used as the basis for translational studies in
human cancer. So how good is this model and what are the pro-
posed “bench to bedside” (or rather “cage to bedside”) applica-
tions? The histology and expression of differentiation markers
such as synaptophysin, neural cell adhesion molecule NCAM
(CD56), calcitonin gene-related peptide, neuron specific eno-
lase, and achaete-scute complex homolog-like (ASCL1) are all
similar to human SCLC. SCLCs usually express gastrin-related
peptides (bombesin) and their receptors, which provide an
autocrine growth signal for the tumors (Sekido et al., 2003;
Zochbauer-Muller et al., 2002). Ideally, the mouse model will
also use this mechanism and thus be of value in preclinical
studies developing therapies directed at blocking this system.
Genome-wide gene expression analysis is another useful
method for comparing the similarities and differences between
this mouse model and human SCLC.
The Meuwissen model exhibits several other important sim-
ilarities to the human disease. First, the coexistence of SCLC
and NSCLC in this model recapitulates the presentation of both
histologies in patients, which can occur at the time of initial diag-
nosis or later as a second primary NSCLC in “cured” SCLC
patients. Thus, the model will be useful in dissecting out
whether, in the setting of both histologies, the tumors are clonal-
ly related or distinct. Second, the Meuwissen et al. model devel-
oped metastases to sites that mimic the human disease. A key
clinical problem is the development of isolated brain metastases
in patients who are otherwise long-term disease-free survivors.
This occurs because the brain acts as a “sanctuary site” from
chemotherapy for microscopic metastatic SCLC. These central
nervous system relapses, besides precluding cure, often leave
the patient debilitated. A clinical approach to this is to give “pro-
phylactic” cranial irradiation (irradiating the brain before there is
any clinical evidence of metastases) (Vines et al., 2003). While
this is effective in preventing the clinical expression of metastat-
ic CNS disease, it, along with the chemotherapy previously
given, may produce substantial cognitive deficits. How and why
this comes about and if it involves a paraneoplastic syndrome
could be worked out in the mouse model using sophisticated
behavioral and learning tests.
Human SCLCs frequently cause “paraneoplastic” syn-
dromes where the tumors produce hormones (such as arginine
vasopressin or adrenocorticotrophic stimulating hormone,
ACTH), which can cause endocrine syndromes such as
hyponatremia (AVP) or Cushing’s syndrome (ACTH) (Beckles et
al., 2003). Another common paraneoplastic manifestation are
autoimmune disorders such as the Eaton Lambert syndrome of
myasthenia related to antibodies developed against SCLC that
react with voltage-gated calcium channels. It will be interesting
to see if similar syndromes develop in the SCLC mouse model.
Perhaps the most important translational aspects to be deter-
mined involve the radiosensitivity and chemosensitivity of these
murine tumors.This includes responsiveness to the same drugs
used in the treatment of human SCLC (such as cisplatin, etopo-
side, and irinotecan) alone and in combination. Ideally, one
would observe similar initial sensitivities as the human tumors
and then relapse with similar types of drug resistance. Were a
similar pattern observed, the model would be extremely useful
in testing new therapies in both initial and relapsed disease.
Fortunately, there are multiple new drugs in development for the
treatment of lung cancer. Well-validated mouse models of the
disease—both SCLC and NSCLC—could be very important in
the evaluation of single agents and combinations, which could
then be tested with greater confidence in the clinic.
When previously untreated SCLC patients are treated with
single drugs, response rates of 20%–40% are seen, and the
rate increases with drug combinations (Sandler, 2003; Turrisi,
2003). However, it is not known whether a tumor that is sensi-
tive to one drug is sensitive to another or whether a tumor
resistant to one might be responsive to something in a different
class. Likewise, it is unclear what causes some patients to
enter a “complete remission,” while others have only a partial
remission or, occasionally, are initially drug resistant. It
appears unlikely that this is solely related to tumor bulk. A
mouse model would allow testing the questions of whether
tumors arising with a very similar genetic background can
develop quite different sensitivities to individual chemotherapy
agents and what are the biochemical mechanisms underlying
these phenotypes. If this heterogeneity exists, it should be pos-
sible to perform expression profiling of the tumors and develop
an expression “signature” that would allow selection of individu-
alized therapy for each tumor. While similar trials are beginning
in humans, it would be hoped that such mouse models would
speed and inform this process. Likewise, there are new thera-
peutic targets and drugs directed at them being developed. It
would seem straightforward to engineer into the mouse model
or obtain mouse lung tumors with these targets and then test
the designer therapy against the model system before entry
into human trials.
A major prerequisite of human SCLC is smoking expo-
sure, which occurs in essentially every patient (Minna et al.,
2002; Wistuba et al., 2001). While smoking damage can lead
to p53 and Rb mutations and allele loss, it undoubtedly does
other things, and it will be important to study the Meuwissen
et al. model under conditions of exposure to cigarette smoke
and its carcinogens and tumor promoters. Microdissection
studies of smoking-damaged bronchial epithelium of SCLC
patients shows dramatically different results from those seen
in other lung cancers (such as squamous and adenocarcino-
mas). In the latter cancers, multiple clonal patches (?100,000
cells in size) are found in the smoking-damaged bronchial
epithelium, while in SCLC, the entire bronchial epithelium
appears to be genetically “scrambled” (Wistuba et al., 2001).
This does not appear related to the amount smoked and so it
will be important to see if similar changes accompany the
mouse model or if this has to be introduced by some other
genetic manipulation (e.g., changes potentially affecting
chromosome stability or DNA repair).
There is a great need to develop early detection and
chemoprevention approaches to lung cancer, and a mouse
model could be a critical reagent in this quest. Thus, it is impor-
tant that the Meuwissen et al. model shows multiple examples
of neuroendocrine cell proliferation in the bronchial specimens,
which probably represent preneoplastic lesions.While these are
occasionally seen in humans, they are very uncommon. Study
of the mouse lesions may lead to ways of detecting similar
lesions in humans, which could aid with early diagnosis. There
is considerable interest in using new proteomic techniques to
develop a blood test for the early detection of cancer (Wulfkuhle
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et al., 2003). It should be possible to use this mouse model with
serum samples in a similar proteomic approach. Given the
genetic, age, and environmental control one has over the
mouse model, it should be possible to get very clean serum
sample proteomic comparisons. These peptide markers can
then be tested in relatively small human trials to see if they are
worth pursing as early detection aids. Also, one can envision
treating the mice with chemoprevention agents being consid-
ered for the clinic to see if these inhibit tumor development. In
fact, it would be of great interest to see if it is even possible to
prevent the progression of lesions that are p53 and Rb null to
frank cancer. The very presence of such mutations may require
the use of conventional cancer chemotherapy agents. Were this
indeed effective, it would raise the prospect (and significant reg-
ulatory challenge) of using cytotoxic chemotherapies with their
attendant toxicities in persons without documented clinical evi-
dence of cancer. In addition, cigarette smoke has tumor promot-
ers, and this model offers the opportunity to study these
promoters and mechanisms of inhibiting them in vivo.
The mouse model of Meuwissen, Berns, and their col-
leagues represents a true breakthrough in the study of SCLC.
From basic tumor biology to early detection to chemotherapy,
this model holds great promise for uncovering some of the keys
to the development of this disease and its management. While
much work remains in the validation and application of this
model, it is poised to make a significant contribution in the fight
against human cancer.
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